Mediwound Stock Price, News & Analysis

MediWound (Nasdaq: MDWD) completed commissioning of its expanded GMP manufacturing facility in Yavne, Israel on November 3, 2025, marking a step toward full operational readiness by year-end 2025. The expansion is expected to increase NexoBrid production capacity by approximately sixfold, aiming to support supply across more than 40 approved markets. The company says the facility will enable a scalable, reliable global supply once regulatory reviews are complete. Market availability remains subject to the completion of those regulatory reviews.

MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, has announced a $30 million registered direct offering of ordinary shares. The company will sell 1,734,105 ordinary shares at $17.30 per share to a prominent U.S.-based mutual fund and healthcare-focused investors.

The offering is expected to close around September 30, 2025, with H.C. Wainwright & Co. serving as the exclusive placement agent. The proceeds will support EscharEx's pre-commercial activities, enhance manufacturing capabilities, and fund general corporate purposes. The offering is made through the company's shelf registration statement on Form F-3.

MediWound (Nasdaq: MDWD) has received marketing authorization from Australia's Therapeutic Goods Administration (TGA) for NexoBrid®, its enzymatic therapy for eschar removal in adult and pediatric burn patients. This approval expands NexoBrid's global presence to 45 countries.

The company's exclusive partner, Balance Medical, plans to launch NexoBrid commercially in Q4 2025. MediWound's manufacturing expansion, scheduled for completion by year-end 2025, will support the Australian launch and growing global demand. The approval represents a strategic entry point into the broader Asia-Pacific market.

MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, announced that its burn debridement therapy NexoBrid® will be featured in 36 scientific presentations at the 21st European Burns Association Congress in Berlin (September 3-6, 2025).

The presentations will showcase data demonstrating NexoBrid's benefits in various patient populations, including pediatric, elderly, and critically burned patients. Key findings highlight improvements in survival, recovery, and scar outcomes, along with advantages in infection control and inflammatory response modulation. Studies also demonstrate NexoBrid's superiority over surgical excision in both routine care and mass casualty scenarios.

MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CEO Ofer Gonen will engage in a fireside chat with Managing Director and Senior Equity Research Analyst Swayampakula Ramakanth on September 8, 2025, at 4:30 PM ET.

Investors can access the live webcast through the company's website in the Events & Presentations section of the Investors page.

MediWound (NASDAQ: MDWD), a leader in enzymatic therapeutics for tissue repair, reported Q2 2025 financial results with revenue of $5.7 million, up 43% from the previous quarter. The company highlighted progress in its VALUE Phase III trial of EscharEx® for venous leg ulcers and established new strategic partnerships with Essity and Convatec.

Key developments include NexoBrid®'s 52% year-over-year U.S. revenue growth and ongoing manufacturing expansion expected to increase production capacity six-fold by year-end 2025. The company received an additional $3.6 million in DoD funding for NexoBrid development. Financial results showed a net loss of $13.3 million, with cash reserves of $32.9 million as of June 30, 2025.

[ "Revenue increased 43% quarter-over-quarter to $5.7 million", "NexoBrid U.S. sales grew 52% year-over-year", "Secured $3.6 million additional DoD funding for NexoBrid development", "Manufacturing capacity expansion to increase NexoBrid production six-fold", "New strategic partnerships established with Essity and Convatec", "Gross margin improved to 23.5% from 8.8% year-over-year" ]

MediWound (Nasdaq: MDWD) has published new Phase II data analysis for EscharEx® in the treatment of venous leg ulcers (VLUs) in Advances in Wound Care journal. The study, analyzing 119 VLU patients, demonstrated a significant correlation between wound bed preparation (WBP) and wound closure.

Key findings revealed that wounds achieving WBP were 4.1 times more likely to close compared to those that did not (p = 0.0004). Notably, wounds failing to achieve WBP had a 90% probability of not healing. Early WBP achievement (within 14 days) showed a significantly increased healing likelihood (Relative Risk = 2.4). The study validates EscharEx's potential in accelerating wound bed preparation for improved healing outcomes.

MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, will release its Q2 2025 financial results on Thursday, August 14, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and provide corporate updates.

Investors can access the call via multiple channels including toll-free numbers for US and Israel, and an international dial-in. A webcast replay will be available in the Investors section of MediWound's website after the call.

MediWound (NASDAQ: MDWD) reported Q1 2025 financial results and provided corporate updates. The company generated $4.0 million in revenue for Q1 2025, down from $5.0 million in Q1 2024, and reported a net loss of $0.7 million ($0.07 per share). Key developments include: Their VALUE Phase III trial for EscharEx in venous leg ulcers is progressing with 216 patients across 40 sites in the U.S. and Europe. The company has secured collaborations with major wound care companies including Solventum, Mölnlycke, MIMEDX, and Kerecis. NexoBrid continues to gain traction with nearly 60 burn centers ordering the product, showing a 207% year-over-year increase in revenue. The company's new manufacturing facility expansion is on track for full operational capacity by end-2025, expected to increase production capacity sixfold. The company maintains a strong financial position with $38.7 million in cash and equivalents as of March 31, 2025, and reaffirmed its full-year 2025 revenue guidance of $24 million.